Arletta Pharma Solutions

Arletta Pharma Solutions is a clinical-stage pharmaceutical company based in Amsterdam, specializing in innovative therapies for women's sexual health. The company's lead asset, Lybrido™, is an on-demand, dual-action oral therapy designed to treat Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). Lybrido™ combines a sublingual testosterone coating with a sildenafil core to address both the psychological and physiological components of sexual dysfunction. Arletta is currently advancing toward pivotal Phase 3 trials in Europe and the United States, building on over fifteen years of scientific research.